SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Manfred Sondermann who wrote (75)7/13/1999 7:03:00 PM
From: glen  Read Replies (1) of 250
 
Manfred, thank you for providing the material in the last two posts. The material certainly adds perspective to VaxGen's vaccine development program.

As an investment, I see this material to be very positive. I conclude that there will be an excellent chance that AIDSVAX will achieve the minimum 30% efficacy threshold, which we are told is all that is needed for FDA approval. At that point, it's a home run that can only turn into a grand slam. VaxGen will not be a one vaccine company, but will continue to produce multiple-strain vaccines, in addition to constantly improving the efficacy of each vaccine.

This model projects tremendous growth opportunities for the company, and I for one, want to have exposure to this upside potential while it is still in its infancy.

Regards,
glen
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News